159 related articles for article (PubMed ID: 30560478)
1. Revefenacin: First Global Approval.
Heo YA
Drugs; 2019 Jan; 79(1):85-91. PubMed ID: 30560478
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
Donohue JF; Feldman G; Sethi S; Barnes CN; Pendyala S; Bourdet D; Crater G
Pulm Pharmacol Ther; 2019 Aug; 57():101808. PubMed ID: 31152911
[TBL] [Abstract][Full Text] [Related]
4. Revefenacin for the treatment of chronic obstructive pulmonary disease.
Li F; Yang J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):293-298. PubMed ID: 30803279
[TBL] [Abstract][Full Text] [Related]
5. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Med; 2019 Jul; 153():38-43. PubMed ID: 31150963
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
[TBL] [Abstract][Full Text] [Related]
8. Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite.
Bourdet DL; Yeola S; Hegde SS; Colson PJ; Barnes CN; Borin MT
Drug Metab Dispos; 2020 Dec; 48(12):1312-1320. PubMed ID: 32978223
[TBL] [Abstract][Full Text] [Related]
9. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Res; 2019 Oct; 20(1):241. PubMed ID: 31666076
[TBL] [Abstract][Full Text] [Related]
10. Revefenacin (Yupelri) for COPD.
Med Lett Drugs Ther; 2019 Jan; 61(1564):14-15. PubMed ID: 30856160
[No Abstract] [Full Text] [Related]
11. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Hvisdas C
Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
[TBL] [Abstract][Full Text] [Related]
12. Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD.
Donohue JF; Mahler DA; Sethi S
Int J Chron Obstruct Pulmon Dis; 2019; 14():2947-2958. PubMed ID: 31908443
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis.
Liu B; Zan S; Luo W
Heart Lung; 2022; 52():52-60. PubMed ID: 34875569
[TBL] [Abstract][Full Text] [Related]
14. Revefenacin for the treatment of chronic obstructive pulmonary disease.
Clark CM; Jacobs DM; Sethi S
Expert Rev Respir Med; 2020 Mar; 14(3):239-247. PubMed ID: 31847629
[No Abstract] [Full Text] [Related]
15. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
ZuWallack AR; ZuWallack RL
Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
[TBL] [Abstract][Full Text] [Related]
16. Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease.
Antoniu SA; Rajnoveanu R; Ulmeanu R; Mihaltan F; Grigore M
Expert Opin Pharmacother; 2020 Jun; 21(9):997-1004. PubMed ID: 32237914
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
Borin MT; Lo A; Barnes CN; Pendyala S; Bourdet DL
Int J Chron Obstruct Pulmon Dis; 2019; 14():2305-2318. PubMed ID: 31632000
[TBL] [Abstract][Full Text] [Related]
18. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
[TBL] [Abstract][Full Text] [Related]
19. Emerging Treatments for COPD: Evidence to Date on Revefenacin.
Lal C; Khan A
COPD; 2020 Feb; 17(1):112-119. PubMed ID: 31833419
[TBL] [Abstract][Full Text] [Related]
20. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
